MINDBIO Aktie

 

    Vancouver, British Columbia – April 1, 2026 – TheNewswire -  MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF) (the “Company” or “MindBio”), a biotechnology company that is commercialising prediction technologies for drug and alcohol intoxication detection using speech analytics and artificial intelligence, is pleased to announce that it has closed its previously announced upsized non-brokered private placement (the “Offering”) for gross proceeds of $1,437,828.87 Pursuant to the Offering, the Company issued an aggregate of 2,396,381 units (each, a “Unit”) at a price of $0.60 per Unit for gross proceeds of $1,437,828.87. Each Unit consists of one common share of the Company (each, a “Share”) and one Share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder to acquire an additional Share at a price of $0.80 for a period of thirty-six months following closing of the Offering, subject to accelerated expiry in the event the closing...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Vancouver, British Columbia – TheNewswire - March 19, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “Company” or “MindBio”), a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection announces today that it is upsizing its non-brokered private placement (the “Offering”) previously announced on February 18, 2026 from $650,000 to up to $1,500,000, pursuant to which the Company intends to now issue up to 2,500,000 units of the Company (the “Units”) at a price of $0.60 per Unit for gross proceeds of up to $1,500,000. Each Unit will consist of one common share of the Company (each, a “Share”) and one Share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder to acquire an additional Share at a price of $0.80 for a period of thirty-six months following closing of the Offering, subject to accelerated expiry in the event the closing price of the Shares on the Canadian S...

Vancouver, British Columbia – TheNewswire - February 24, 2026 – MindBio Therapeutics Corp. (CSE: MBIO | Frankfurt: WF6 | OTCQB: MBQIF) (“MindBio” or the “Company”), a biotechnology innovator commercializing AI-powered voice analytics for real-time drug and alcohol impairment detection, today announced the appointment of Felipe Leyton — one of South America's most influential drug and alcohol policy architects and a recognized mining industry safety authority — to lead commercialization across the South American mining sector. Mr. Leyton was part of the technical and operational implementation of Chile's landmark Zero Tolerance framework for alcohol-impaired driving and will now spearhead deployment of MindBio's Voice-Initiated AI Drug & Alcohol Screening Platform into one of the world's largest and highest-risk industrial markets. This appointment represents a significant inflection point as MindBio transitions from advanced development to commercial field deployment. (0.b)National...

US88706T1088 KYG8918W1069 VGG878801114 CA87357T3001 FI4000176557 BMG3775G1539 CNE1000004H7 CNE1000001C4 HK0000981941 CNE100007F72 JP3535800001 US8740361063 KYG910191363 HK0000827664 BRUSIMACNOR3 ID1000191109 SE0017769136 SGXE24586385 GB00BN4M3M55 ES0105670006 GB00BMBVXB73 ES0105650008 ES0105650073 KYG0958D1060 CA88089G2027 CNE100005RV4 GB00BNBQZW49 AU000000EGH7 US84612H1068 US33744V1035 CA00686A1084 ID1000058407 AU0000312480 SE0017616006 SE0010102095 US69355M1071 US96145W1036 US2316472073 CNE100007DW8 ES0105618005 KYG2050P1028 AU0000150351 SE0017082514 GB00BLR8T846 CA59100N1042 KYG2117N1088 AU000000LIN6 HK0345001611 GB0001482891 AU000000DCC9 SG1J24887775 CNE100006JG0 JP3960000002 CA58046P1080 CH0210362643 IT0005678104 ZAE000167391 PLRNDCB00011 CA37150L1031 CA3638821015 ID1000100209 US9426221019 BMG8403G1033 CA60256C2076 BMG2118X1056 PLBRTZM00010 PLYLWHT00012 CA18914M2076 US9396531017 CNE100003F19 SE0017486103 KYG5244R1083 US98419J3059...

Vancouver, British Columbia - TheNewswire - February 18, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “Company” or “MindBio”), a biotechnology company that is commercialising prediction technologies for drug and alcohol intoxication detection using speech analytics and artificial intelligence, is pleased to announce it will conduct a non-brokered private placement (the “Offering”) to raise gross proceeds of up to $650,000 to accelerate the development of its enterprise intoxication detection solution, including the production of proprietary hardware and edge technologies for remote deployment in the mining industry. The Company will offer up to 1,083,333 units (each, an “Unit”) at a price of $0.60 per Unit for gross proceeds of up to $650,000. Each Unit will consist of one common share of the Company (each, a “Share”) and one Share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder to acquire an additional Share...

Vancouver, British Columbia – TheNewswire - February 18, 2026 – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6) (OTCQB: MBQIF) (“MindBio” or the “Company”), a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection, today announced it has commenced development of a proprietary edge computing platform, including dedicated hardware, to enable large-scale deployment in the mining industry. The Company is working with an experienced engineering firm with expertise in hardware and sensor development to design and manufacture the Company's integrated Edge AI solution for real-time, on-device voice analysis in remote and infrastructure-limited environments. Prototype development is nearing completion, with hardware manufacturing and field-ready deployment expected in Q2 2026. The MindBio hardware device will be sold direct and via distribution channels. Every device will also have a recurring revenue stream for use of the installed software...

Vancouver, British Columbia – TheNewswire - February 4, 2026 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), is pleased to report following its recent success in meeting with mining and health executives in South America, it has deployed a team of software engineers to the mining industry in country. The team deployed will be working with health and mining officials to build a protocol for practical implementation of drug and alcohol screening by voice.   The voice analytics enterprise solution being developed by MindBio's engineers is a game changer for intoxication detection in the mining industry, aviation and construction and where high-volume testing at scale for a variety of drugs and alcohol presents major challenges for management and law enforcement, is time consuming, physically invasive and expensive.   The Company's CEO Justin Hanka said, “MindBio is seizing its first mover advantage in voice activated AI digital health di...

CEO Meets with Mining and Health Executives in South America to discuss deployment of new drug and alcohol screening solution.  Mining deployment of the technology would disrupt drug and alcohol testing in the mining industry and represents a massive global opportunity for the Company.  Voice activated solution would enable drug and alcohol screening at the gate and at scale.    Vancouver, British Columbia – TheNewswire - February 2, 2026 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), a biotechnology company that conducts clinical health research and has developed a world first AI prediction tool for drug and alcohol intoxication detection by a simple analysis of the voice, is pleased to announce its CEO, Justin Hanka has met with mining and health executives in South America, to discuss potential deployment of the Company's technology into the mining industry.   The Company has been showcasing its technology as an enterprise solut...

  Vancouver, British Columbia – TheNewswire - January 27, 2026 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), a biotechnology company that conducts clinical health research and has developed a world first AI prediction tool for drug and alcohol intoxication detection by a simple analysis of the voice, is pleased to announce the Company is targeting the global digital health diagnostics market with a first mover advantage in using speech as a diagnostic tool in drug and alcohol intoxication detection. The voice is a powerful biomarker that can be used to assess and predict internal health and disease states.  The Company uses sophisticated machine learning models, developed during years of clinical trials, to analyse voice data and make predictions that are clinically meaningful and useful in a variety of consumer and enterprise situations. The Company has developed and commercialised a technology, activated by a simple analysis of the v...

  Vancouver, British Columbia – TheNewswire - January 21, 2026 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), a biotechnology company that conducts clinical health research and has developed a world first AI prediction tool for drug and alcohol intoxication detection using voice, is pleased to announce the Company has launched an extended showcase of its Voice and AI powered intoxication detection technology in the USA.  The showcase comes as the Company lists its common shares for trading on the OTCQB Market. The Company has developed and commercialised a technology, activated by the voice and powered by AI to predict intoxication.  The Company has amassed large amounts of data from drug and alcohol clinical trials and has developed proprietary algorithms as the basis for its prediction technologies with remarkable accuracy for the detection of alcohol and hallucinogenic drugs. The Company intends to expand its intoxication detection ...

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA92338D1015 Verano Holdings Corp. 05.11.2025 US92339H1014 Verano Holdings Corp. 06.11.2025 Tausch 1:1 CA00792D1033 Advanced Gold Exploration Inc. 05.11.2025 CA00792D2023 Advanced Gold Exploration Inc. 06.11.2025 Tausch 10:1 CA2902571041 Else Nutrition Holding Inc. 05.11.2025 CA2902575000 Else Nutrition Holding Inc. 06.11.2025 Tausch 10:1 CA60256C1086 MindBio Therapeutics Corp. 05.11.2025 CA60256C2076 MindBio Therapeutics Corp. 06.11.2025 Tausch 400:1...